Loading...
01/11 05:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite positive aspects like cash burn reduction and international interest, the earnings miss, revenue headwinds, and grant funding issues weigh heavily. The registered direct offering dilutes shares, and management's vague responses in the Q&A raise concerns. The negative sentiment is further exacerbated by the weak financial performance and uncertain guidance, suggesting a likely stock price decline of -2% to -8%.
Revenue $2.1 million, down from previous expectations due to longer deal timing and loss of several deals at large academic institutions funded by grants.
Gross Profit $0.9 million, with a gross margin of 41.3%, representing a 20 basis point improvement year-over-year.
R&D Expenses $5.0 million, down from $5.6 million in Q1 2024.
Sales, General and Administrative Expenses $6.7 million, up from $6.4 million in Q1 2024.
Net Loss $9.4 million, or $0.12 per share, compared to a net loss of $9.8 million or $0.14 per share in the same period of the prior year.
Net Cash Burn $4.6 million, with a net cash burn excluding financing of $10.1 million, down 16% from $12.0 million in 2024.
Cash and Cash Equivalents $33.1 million as of March 31, 2025, including $6 million from registered direct financing.
Total Cash Burn for 2025 Expected to be in the range of $25 million to $28 million, representing a 31% decline year-over-year at the midpoint.
Gross Margin Outlook for 2025 Expected to be in the range of 47% to 50%, representing a 280 basis point increase year-over-year at the midpoint.
Next Generation Software Clearance: Expected clearance for next generation software in the first-half of 2025, with commercial rollout in the second-half.
Swoop System Technology Launch: Working towards clearance and launch of another generation of Swoop System Technology later this year, promising significant improvements in image quality.
NEURO PMR Study: Enrollment for the NEURO PMR study is progressing well, with expectations to conclude ahead of previous estimates by the end of Q3 2025.
International Market Expansion: Anticipating regulatory approval and market entrance in India in the second-half of 2025.
Office Business Launch: Plans to launch the office business mid-2025, with pilot accounts and training for field teams already initiated.
Emergency Department Expansion: Continued expansion into emergency departments as an additional call point in hospitals.
Cash Burn Reduction: Completed a reorganization to reduce cash burn and extended cash run rate to the end of 2026.
Sales Team Training: Training for new sales personnel to build awareness of next generation imaging technology.
Diversified Revenue Strategy: Transitioning from reliance on U.S. hospital deals to a diversified portfolio including hospitals, office settings, and international markets.
Growth Catalyst: Expecting significant growth in the second-half of 2025 driven by new product launches and market expansion.
Earnings Miss: Hyperfine, Inc. reported an EPS of $-0.14, missing expectations of $-0.12.
Revenue Headwinds: The company experienced revenue headwinds due to a new political environment, resulting in the loss of several deals at large academic institutions funded by grants.
Sales Cycle Variability: Sales cycles for U.S. hospitals are protracted and exhibit high variability, impacting deal timing.
Grant Funding Cancellations: Significant reductions and cancellations of grant funding to academic institutions have led to lost deals.
Cash Burn: The company reported a net cash burn of $10.1 million excluding financing, with a total cash burn expected to be in the range of $25 million to $28 million for the full year 2025.
Tariff Monitoring: Hyperfine is monitoring government actions regarding tariffs, which could potentially impact the business.
Revenue Diversification: Hyperfine is transitioning from a reliance on U.S. hospital deals to a diversified revenue model across hospitals, office settings, and international markets.
Product Development: The company is focused on launching next-generation imaging technology with significant improvements in image quality, expected to roll out in the second half of 2025.
Clinical Studies: The NEURO PMR study is underway, with strong enrollment and enthusiasm for the Swoop system, expected to conclude by the end of Q3 2025.
International Expansion: Hyperfine anticipates regulatory approval and market entry in India in the second half of 2025.
Revenue Guidance: For the first half of 2025, revenue is expected to be between $5 million and $6 million, with full-year growth projected at 10% to 20% over 2024.
Gross Margin Guidance: Gross margin is expected to be between 47% and 50% for the full year, with second-half margins anticipated to exceed first-half margins.
Cash Burn Guidance: Total cash burn for 2025 is projected to be between $25 million and $28 million, a 31% decline year-over-year.
Cash Runway: The company has extended its cash runway to the end of 2026.
Registered Direct Offering: Raised $6 million through a registered direct offering to extend cash run rate to the end of 2026.
Cash Burn: Total cash burn expected to be in the range of $25 million to $28 million for the full-year 2025, representing a 31% decline in cash burn on a year-over-year basis.
The earnings call highlights strong financial performance with a 27% revenue increase and record gross margins, driven by new product launches. Although the company remains unprofitable, reduced cash burn and a robust pipeline suggest positive momentum. The Q&A reveals cautious optimism, with management focusing on near-term growth and international expansion challenges. The lack of 2026 guidance is a minor concern but is offset by positive indicators like increased sales and cash optimization, leading to a positive sentiment.
The earnings call summary and Q&A session reflect a positive outlook. Despite a slight net loss, the company shows strong financial discipline with reduced expenses and cash burn. Revenue guidance indicates significant growth, supported by new product launches and international expansion. The Q&A session highlights management's confidence in revenue drivers and market opportunities. While some responses lacked specificity, the overall sentiment is positive due to improved financial metrics, promising guidance, and strategic growth initiatives.
Despite positive aspects like cash burn reduction and international interest, the earnings miss, revenue headwinds, and grant funding issues weigh heavily. The registered direct offering dilutes shares, and management's vague responses in the Q&A raise concerns. The negative sentiment is further exacerbated by the weak financial performance and uncertain guidance, suggesting a likely stock price decline of -2% to -8%.
The earnings call reveals several negative factors: revenue decline due to political changes, loss of grant-funded deals, and prolonged sales cycles. While there are positive elements like cash burn reduction and international interest, the Q&A highlights uncertainties in grant recovery and unclear international contributions. The registered direct offering could dilute stock value. Despite optimistic guidance for the second half, the current negative trends and uncertainties outweigh the positives, leading to a negative sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
